<DOC>
	<DOC>NCT02416999</DOC>
	<brief_summary>This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.</brief_summary>
	<brief_title>Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas</brief_title>
	<detailed_description>This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas. And, this trial is approved by medical ethics committee of Hebei Yanda Hospital.Researchers will conduct thsi trial from 2015/05 to 2018/05, and 30 recurrent high-grade glioma patients will be recruited. Patients who are recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>High grade glioma was diagnosed by postoperation pathological method, and shows a relapse. Before included, the patient needs imageological examinations, and the diameter of contrast enhancing area is bigger than 1cm, PET or MRS results show positive features. The age of patient should be between 18 years old and 70 years old. The condition of the patient permits the treatment of ultralow dose Bevacizumab plus Temozolomide. The patient is informed consent,and willing to join in this research. The diagnosis is not recurrent highgrade glioma. The diagnosis of highgrade glioma was not established by pathological method. The results of imageological examinations do not meet the standard of including. The age of the patient does not meet the requirement of this research. The condition of the patient does not permit the treatment of ultralow dose Bevacizumab plus Temozolomide. There are other conditions that the clinicians believe that the treatment of ultralow dose Bevacizumab plus Temozolomide is not appropriate for the patient. The patient is not willing to join in this research.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>glioma</keyword>
	<keyword>high-grade glioma</keyword>
</DOC>